HK1083749A1 - Solid nano pharmaceutical formulation and preparation method thereof - Google Patents

Solid nano pharmaceutical formulation and preparation method thereof

Info

Publication number
HK1083749A1
HK1083749A1 HK06103801.7A HK06103801A HK1083749A1 HK 1083749 A1 HK1083749 A1 HK 1083749A1 HK 06103801 A HK06103801 A HK 06103801A HK 1083749 A1 HK1083749 A1 HK 1083749A1
Authority
HK
Hong Kong
Prior art keywords
preparation
pharmaceutical formulation
solid nano
nano pharmaceutical
solid
Prior art date
Application number
HK06103801.7A
Other languages
English (en)
Inventor
Yunqing Liu
Xiying Liu
Wei Liu
Tong Liu
Original Assignee
Yunqing Liu
Xiying Liu
Wei Liu
Tong Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB021288453A external-priority patent/CN100479807C/zh
Priority claimed from CNA021491461A external-priority patent/CN1502332A/zh
Application filed by Yunqing Liu, Xiying Liu, Wei Liu, Tong Liu filed Critical Yunqing Liu
Publication of HK1083749A1 publication Critical patent/HK1083749A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06103801.7A 2002-08-15 2006-03-27 Solid nano pharmaceutical formulation and preparation method thereof HK1083749A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB021288453A CN100479807C (zh) 2002-08-15 2002-08-15 药物输送系统——固体纳米药物的制备方法
CNA021491461A CN1502332A (zh) 2002-11-25 2002-11-25 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法
PCT/CN2003/000663 WO2004022100A1 (fr) 2002-08-15 2003-08-13 Formulation nanopharmaceutique et son procede de preparation

Publications (1)

Publication Number Publication Date
HK1083749A1 true HK1083749A1 (en) 2006-07-14

Family

ID=31979238

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103801.7A HK1083749A1 (en) 2002-08-15 2006-03-27 Solid nano pharmaceutical formulation and preparation method thereof

Country Status (9)

Country Link
US (1) US20050255164A1 (xx)
EP (1) EP1543841A4 (xx)
JP (1) JP2006500387A (xx)
KR (1) KR20060021278A (xx)
CN (1) CN100518831C (xx)
AU (1) AU2003257791A1 (xx)
CA (1) CA2495899A1 (xx)
HK (1) HK1083749A1 (xx)
WO (1) WO2004022100A1 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806129A1 (en) * 2004-10-01 2007-07-11 Eisai R&D Management Co., Ltd. Composition containing fine particles and process for producing the same
WO2007076295A2 (en) * 2005-12-16 2007-07-05 University Of Kansas Nanoclusters for delivery of therapeutics
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
WO2007142440A1 (en) * 2006-06-02 2007-12-13 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same
CN101511348B (zh) * 2006-08-30 2012-04-18 国立大学法人九州大学 含有包封他汀类之纳米颗粒的药物组合物
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
EP1952803A1 (en) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
EP2675434A1 (en) 2011-02-17 2013-12-25 F.Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
NZ708272A (en) 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
CN104013601A (zh) * 2014-06-06 2014-09-03 重庆医科大学 姜黄色素羟丙环糊精磷脂纳米粒及其制备方法
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
CN106092861B (zh) * 2016-05-26 2019-02-26 国家纳米科学中心 用于纳米颗粒的光谱椭偏拟合方法
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
KR20190141244A (ko) 2017-05-03 2019-12-23 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 및 부설판을 함유하는 조성물
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DK0695169T3 (da) * 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
JPH10500982A (ja) * 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
HUP9701945A3 (en) * 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
IL140218A0 (en) * 1998-06-16 2002-02-10 Microwave Solutions Ltd Oscillator circuit
FR2792942B1 (fr) * 1999-04-29 2001-06-08 Commissariat Energie Atomique Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
ES2272496T3 (es) * 2000-02-04 2007-05-01 Lipoxen Technologies Limited Procedimiento de deshidratacion/rehidritacion para la preparacion de lipososmas.
CN1165305C (zh) * 2002-12-13 2004-09-08 北京东方天翔医药技术开发有限公司 尼莫地平冻干组合物

Also Published As

Publication number Publication date
US20050255164A1 (en) 2005-11-17
EP1543841A4 (en) 2011-03-16
WO2004022100A1 (fr) 2004-03-18
CN100518831C (zh) 2009-07-29
JP2006500387A (ja) 2006-01-05
CA2495899A1 (en) 2004-03-18
AU2003257791A1 (en) 2004-03-29
KR20060021278A (ko) 2006-03-07
CN1674941A (zh) 2005-09-28
EP1543841A1 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
HK1083749A1 (en) Solid nano pharmaceutical formulation and preparation method thereof
TWI319319B (en) New solid pharmaceutical formulations comprising telmisartan and preparation thereof
TWI349664B (en) Benzimidazole derivatives: preparation and pharmaceutical applications
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
GB2402063B (en) Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof
HK1093508A1 (en) Derivatives of diperdinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in preparation of drugs
IL173726A (en) Pharmaceutical compositions containing n-n-dihaloamino acids and their uses
HK1089394A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
TWI319318B (en) Modified release pharmaceutical formulation
HK1074792A1 (en) An anti-rheumatism medicament and method to prepare thereof
IL163868A (en) Hemiasterlin derivatives and pharmaceutical compositions comprising them
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
IL152900A0 (en) Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
IL165069A0 (en) Immediate release pharmaceutical formulation
SI1673349T1 (sl) Derivati benzimidazola: priprava in farmacevtske uporabe
HK1078469A1 (en) Pharmaceutical and cosmetic compositions comprising plgf-1
AU2003252493A1 (en) Pharmaceutical composition containing decoy and method of using the same
EP1581258A4 (en) PHARMACEUTICAL FORMULATION AND MANUFACTURING METHOD THEREFOR
IL174081A0 (en) Formulation for obtaining a pharmaceutical composition, methods of obtaining and use thereof
GB0304540D0 (en) Particle formulation and its preparation
PL375762A1 (en) Nasallly applicable pharmaceutical preparation and the production thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130813